Nektar Therapeutics (NKTR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nektar Therapeutics (NKTR) has a cash flow conversion efficiency ratio of -0.077x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.30 Million) by net assets ($576.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nektar Therapeutics liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Nektar Therapeutics - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Nektar Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Nektar Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nektar Therapeutics ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northwest Natural Gas Co
NYSE:NWN
|
0.074x |
|
Navios Maritime Partners LP Unit
NYSE:NMM
|
0.037x |
|
Zhejiang Semir Garment Co Ltd
SHE:002563
|
-0.018x |
|
Central China Securities Co Ltd
SHG:601375
|
0.335x |
|
Atul Limited
NSE:ATUL
|
0.081x |
|
Sichuan Swellfun Co Ltd
SHG:600779
|
-0.068x |
|
OCADO GROUP SP.ADR 1/2
F:0OC1
|
N/A |
|
Weifu High-Technology Group Co Ltd
SHE:000581
|
0.049x |
Annual Cash Flow Conversion Efficiency for Nektar Therapeutics (1994–2025)
The table below shows the annual cash flow conversion efficiency of Nektar Therapeutics from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see NKTR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $89.83 Million | $-208.51 Million | -2.321x | +19.77% |
| 2024-12-31 | $60.74 Million | $-175.71 Million | -2.893x | -96.74% |
| 2023-12-31 | $130.99 Million | $-192.61 Million | -1.470x | -77.34% |
| 2022-12-31 | $366.64 Million | $-304.01 Million | -0.829x | -36.54% |
| 2021-12-31 | $679.51 Million | $-412.66 Million | -0.607x | -108.83% |
| 2020-12-31 | $1.08 Billion | $-313.29 Million | -0.291x | -24.35% |
| 2019-12-31 | $1.41 Billion | $-328.68 Million | -0.234x | -155.93% |
| 2018-12-31 | $1.72 Billion | $718.21 Million | 0.418x | +145.67% |
| 2017-12-31 | $87.83 Million | $-80.41 Million | -0.916x | +31.05% |
| 2016-12-31 | $88.12 Million | $-117.02 Million | -1.328x | +88.32% |
| 2015-12-31 | $6.43 Million | $-73.08 Million | -11.368x | -190.84% |
| 2014-12-31 | $36.33 Million | $-142.01 Million | -3.909x | -1012.07% |
| 2013-12-31 | $-89.90 Million | $-38.53 Million | 0.429x | +115.53% |
| 2012-12-31 | $47.02 Million | $-129.76 Million | -2.760x | -379.95% |
| 2011-12-31 | $197.81 Million | $-113.74 Million | -0.575x | +6.69% |
| 2010-12-31 | $90.66 Million | $-55.87 Million | -0.616x | -258.75% |
| 2009-12-31 | $102.37 Million | $39.74 Million | 0.388x | +150.64% |
| 2008-12-31 | $190.15 Million | $-145.78 Million | -0.767x | -212.37% |
| 2007-12-31 | $214.44 Million | $146.30 Million | 0.682x | +267.08% |
| 2006-12-31 | $227.06 Million | $-92.72 Million | -0.408x | -71.09% |
| 2005-12-31 | $326.81 Million | $-78.00 Million | -0.239x | -42.74% |
| 2004-12-31 | $467.34 Million | $-78.14 Million | -0.167x | +63.97% |
| 2003-12-31 | $164.19 Million | $-76.20 Million | -0.464x | -27.99% |
| 2002-12-31 | $206.77 Million | $-74.97 Million | -0.363x | -93.04% |
| 2001-12-31 | $270.31 Million | $-50.77 Million | -0.188x | -46.04% |
| 2000-12-31 | $277.88 Million | $-35.74 Million | -0.129x | +27.34% |
| 1999-12-31 | $86.63 Million | $-15.33 Million | -0.177x | -6.70% |
| 1998-12-31 | $115.88 Million | $-19.22 Million | -0.166x | -423.49% |
| 1997-12-31 | $97.09 Million | $4.98 Million | 0.051x | +131.03% |
| 1996-12-31 | $35.10 Million | $-5.80 Million | -0.165x | +37.02% |
| 1995-12-31 | $20.20 Million | $-5.30 Million | -0.262x | -1.01% |
| 1994-12-31 | $15.40 Million | $-4.00 Million | -0.260x | -- |
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosi… Read more